Administration Agrees to Reopen Review of Frozen NIH Grant Applications

The Trump administration on Monday agreed to return a defined set of stalled National Institutes of Health grant applications to the agency’s ordinary scientific review process, according to a court filing in the U.S. District Court for the District of Massachusetts dated December 29, 2025. The procedural settlement follows a lawsuit brought by a group of researchers and several Democratic led states challenging a policy shift that had halted or rejected proposals tied to certain priority areas.

Under the agreement, NIH will subject the listed submissions to the agency’s standard peer review procedures rather than excluding them on the basis of the administration’s directives. The filing makes clear that the remedy is narrowly procedural. It requires new scientific evaluations, it does not compel NIH to fund any particular proposal, and it leaves in place the agency’s discretion to decide awards based on merit and budgetary priorities.

The applications at issue cover projects that plaintiffs and court papers describe as addressing key public health priorities. Examples cited in litigation include research on HIV prevention, Alzheimer’s disease, healthcare outcomes for LGBTQ communities, and studies into sexual violence. Advocates for the researchers said that returning those proposals to peer review restores a measure of fairness for work that had been sidelined after the administration issued language steering research dollars away from initiatives it associated with diversity, equity and inclusion or so called gender ideology.

The procedural settlement resolves part of a broader legal dispute. Earlier in the case a federal judge in Boston found that NIH had unlawfully canceled hundreds of millions of dollars in research grants because of their perceived connection to diversity related initiatives. That ruling underpins the court’s willingness to require renewed review for an enumerated set of applications, but it did not resolve the larger questions about how the administration’s directives should be interpreted or whether those directives themselves are lawful.

For researchers, the agreement offers both relief and uncertainty. The return to routine scientific review could revive projects that address underserved populations and urgent disease challenges, and it may preserve careers and institutional investments that were jeopardized by the freezes. At the same time the lack of any funding guarantee means many investigators will still face delays, interrupted timelines, and the prospect of reapplication in a constrained research budget environment.

The dispute highlights the tensions that can arise when political directives intersect with scientific funding mechanisms. Experts and advocates contend that peer review is intended to insulate grant decisions from political preferences so that merit and public health need guide allocations. Critics of the administration argue that steering funds away from research tied to diversity or social determinants of health risks narrowing the scientific agenda and harming communities that rely on targeted studies.

With the agreement in hand, NIH is expected to move ahead with the specified reviews, although the filing does not spell out precise timelines. The broader litigation over the administration’s policy language and its treatment of DEI related research remains unresolved, and further court proceedings are anticipated as the parties press their arguments about how federal research priorities should be set and protected.